

CADTH RAPID RESPONSE REPORT:  
SUMMARY WITH CRITICAL APPRAISAL

# Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety

Service Line: Rapid Response Service  
Version: 1.0  
Publication Date: June 14, 2019  
Report Length: 22 Pages

**Authors:** Srabani Banerjee, Suzanne McCormack

**Cite As:** *Acetylcysteine for Patients Requiring Mucous Secretion Clearance: A Review of Clinical Effectiveness and Safety*. Ottawa: CADTH; 2019 Jun. (CADTH rapid response report: summary with critical appraisal).

**ISSN:** 1922-8147 (online)

**Disclaimer:** The information in this document is intended to help Canadian health care decision-makers, health care professionals, health systems leaders, and policy-makers make well-informed decisions and thereby improve the quality of health care services. While patients and others may access this document, the document is made available for informational purposes only and no representations or warranties are made with respect to its fitness for any particular purpose. The information in this document should not be used as a substitute for professional medical advice or as a substitute for the application of clinical judgment in respect of the care of a particular patient or other professional judgment in any decision-making process. The Canadian Agency for Drugs and Technologies in Health (CADTH) does not endorse any information, drugs, therapies, treatments, products, processes, or services.

While care has been taken to ensure that the information prepared by CADTH in this document is accurate, complete, and up-to-date as at the applicable date the material was first published by CADTH, CADTH does not make any guarantees to that effect. CADTH does not guarantee and is not responsible for the quality, currency, propriety, accuracy, or reasonableness of any statements, information, or conclusions contained in any third-party materials used in preparing this document. The views and opinions of third parties published in this document do not necessarily state or reflect those of CADTH.

CADTH is not responsible for any errors, omissions, injury, loss, or damage arising from or relating to the use (or misuse) of any information, statements, or conclusions contained in or implied by the contents of this document or any of the source materials.

This document may contain links to third-party websites. CADTH does not have control over the content of such sites. Use of third-party sites is governed by the third-party website owners' own terms and conditions set out for such sites. CADTH does not make any guarantee with respect to any information contained on such third-party sites and CADTH is not responsible for any injury, loss, or damage suffered as a result of using such third-party sites. CADTH has no responsibility for the collection, use, and disclosure of personal information by third-party sites.

Subject to the aforementioned limitations, the views expressed herein are those of CADTH and do not necessarily represent the views of Canada's federal, provincial, or territorial governments or any third party supplier of information.

This document is prepared and intended for use in the context of the Canadian health care system. The use of this document outside of Canada is done so at the user's own risk.

This disclaimer and any questions or matters of any nature arising from or relating to the content or use (or misuse) of this document will be governed by and interpreted in accordance with the laws of the Province of Ontario and the laws of Canada applicable therein, and all proceedings shall be subject to the exclusive jurisdiction of the courts of the Province of Ontario, Canada.

The copyright and other intellectual property rights in this document are owned by CADTH and its licensors. These rights are protected by the Canadian *Copyright Act* and other national and international laws and agreements. Users are permitted to make copies of this document for non-commercial purposes only, provided it is not modified when reproduced and appropriate credit is given to CADTH and its licensors.

**About CADTH:** CADTH is an independent, not-for-profit organization responsible for providing Canada's health care decision-makers with objective evidence to help make informed decisions about the optimal use of drugs, medical devices, diagnostics, and procedures in our health care system.

**Funding:** CADTH receives funding from Canada's federal, provincial, and territorial governments, with the exception of Quebec.

**Questions or requests for information about this report can be directed to [Requests@CADTH.ca](mailto:Requests@CADTH.ca)**

## Abbreviations

CI	confidence interval
COPD	chronic obstructive pulmonary disease
OR	Odds ratio
RCT	randomized controlled trial
RD	risk difference
RR	relative risk

## Context and Policy Issues

Mucus secretion clearance is a defense mechanism used by the lung to protect itself from pathogens and particles present in the inhaled air.<sup>1,2</sup> Mucus traps pathogens and particles in inhaled air, and is usually cleared from the lungs and airways by airflow and ciliary hairs.<sup>2</sup> Impaired mucous clearance results in abnormal lung function.<sup>3</sup>

Mucus is a viscoelastic gel-like substance and consists of glycoproteins known as mucins, mixed with other proteins, lipids and water.<sup>2</sup> In healthy individuals, mucus has low viscosity and elasticity and is easily cleared, however in certain lung diseases the mucus has higher viscosity and elasticity and is not easily cleared. Pharmacologic treatments for impaired mucous secretion clearance include agents such as isotonic saline, hypertonic saline, dornase alpha, and acetylcysteine (also known as N-acetylcysteine [NAC]). NAC hydrolyzes the disulfide bonds of mucus proteins to decrease mucus viscosity, thereby facilitating its clearance.<sup>4</sup> NAC is used as a treatment option in various conditions in which there are problems with clearance of lung mucosal secretions (such as chronic obstructive pulmonary disease [COPD], chronic bronchitis, and intubated or post-operative patients).<sup>1,4-7</sup>

The purpose of this report is to review the comparative clinical effectiveness and safety of NAC for treating adult patients requiring mucous secretion clearance. Additionally, for this patient population, the clinical effectiveness of treatment with nebulized acetylcysteine versus oral acetylcysteine will be reviewed. A subsequent report will review the evidence-based guidelines regarding NAC for the treatment of adult patients requiring mucous secretion clearance.

## Research Questions

1. What is the comparative clinical effectiveness of acetylcysteine versus other treatments for patients requiring mucous secretion clearance?
2. What is the evidence regarding the safety of acetylcysteine when used for patients requiring mucous secretion clearance?
3. What is the comparative clinical effectiveness of nebulized acetylcysteine versus oral acetylcysteine for patients requiring mucous secretion clearance?

## Key Findings

Relevant clinical effectiveness data were sparse. Mucous expectoration, mucous viscosity, and oxygenation tended to improve with acetylcysteine (NAC) compared with isotonic saline (IS), however the between-group differences were either not statistically significant or statistical significance was not reported.

For patients with chronic obstructive pulmonary disease or chronic bronchitis, or hospitalized patients with acute lung disease, findings were variable with respect to adverse events for treatment with NAC compared with placebo, and definitive conclusions were not possible. Other safety-related outcomes for the comparison of NAC versus placebo, such as hospitalization, atelectasis, and mortality, were sparsely reported and results were variable. Similarly, evidence for the safety of NAC compared to IS was sparse and definite conclusions were not possible.

No relevant evidence regarding the comparative clinical effectiveness of nebulized NAC versus oral NAC for patients requiring mucous secretion clearance were identified.

## Methods

### Literature Search Methods

A limited literature search was conducted by an information specialist on key resources including MEDLINE, Embase, the Cochrane Library, University of York Centre for Reviews and Dissemination (CRD) databases, Canadian and major international health technology agencies, as well as a focused Internet search. The search strategy was comprised of both controlled vocabulary, such as the National Library of Medicine’s MeSH (Medical Subject Headings), and keywords. The main search concepts were acetylcysteine and mucus or mucous secretions. No filters were applied to limit the retrieval by study type. Where possible, retrieval was limited to the human population. The search was also limited to English-language documents published between January 1, 2014 and May 17, 2019.

### Selection Criteria and Methods

One reviewer screened citations and selected studies. In the first level of screening, titles and abstracts were reviewed and potentially relevant articles were retrieved and assessed for inclusion. The final selection of full-text articles was based on the inclusion criteria presented in Table 1.

**Table 1: Selection Criteria**

<b>Population</b>	Adult patients, in any setting, requiring mucous secretion clearance
<b>Intervention</b>	Q1: Nebulized or oral acetylcysteine; nebulized acetylcysteine in combination with saline; nebulized acetylcysteine in combination with salbutamol (either nebulized or inhaled via a metered dose inhaler) Q2: Nebulized or oral acetylcysteine; nebulized acetylcysteine in combination with saline Q3: Nebulized acetylcysteine; nebulized acetylcysteine in combination with saline
<b>Comparator</b>	Q1,2: Dornase alfa; guaifenesin; hypertonic saline; isotonic saline; inhaled mannitol; non-drug measures (e.g., mobilization, hydration, percussions, mechanical aspiration) Q2: Placebo, no comparator Q3: Oral acetylcysteine
<b>Outcomes</b>	Q1,3: Effectiveness (e.g., mucus clearance, decreased mucus production; improvements in wheeze and cough frequency, exacerbations, lung function, quality of life, improvements in dyspnea); Q2: Safety (e.g. adverse events, side effects, admission to hospital, mortality)
<b>Study Designs</b>	Health technology assessments, systematic reviews/meta-analyses, randomized controlled trials, and non-randomized studies

## Exclusion Criteria

Studies were excluded if they did not meet the selection criteria outlined in Table 1, they were duplicate publications, or were published prior to 2014. Studies which included a mixed population (adult and pediatric) were excluded unless results were presented separately for adults. Studies already included in a selected systematic review were excluded.

## Critical Appraisal of Individual Studies

The included systematic reviews were critically appraised by one reviewer using AMSTAR 2,<sup>8</sup> and the included randomized controlled trial (RCT) was critically appraised based on the Downs and Black checklist.<sup>9</sup> Summary scores were not calculated for the included studies; rather, the strengths and limitations of each individual study were described narratively.

## Summary of Evidence

### Quantity of Research Available

A total of 323 citations were identified in the literature search. Following screening of titles and abstracts, 301 citations were excluded and 22 potentially relevant reports from the electronic search were retrieved for full-text review. One potentially relevant publication was retrieved from the grey literature search for full text review. Of these potentially relevant articles, 17 publications were excluded for various reasons, and six publications met the inclusion criteria and were included in this report. These comprised five systematic reviews,<sup>1,4-7</sup> and one RCT,<sup>10</sup>. Appendix 1 presents the PRISMA<sup>11</sup> flowchart of the study selection.

### Summary of Study Characteristics

Study characteristics are summarized in the following sections and additional details are provided in Appendix 2, Table 2 and Table 3.

#### *Study Design*

Five relevant systematic reviews<sup>1,4-7</sup> were selected. One systematic review<sup>7</sup> included two relevant RCTs with ventilated or post-operative patients. One systematic review<sup>4</sup> included four relevant RCTs with hospitalized patients. Three systematic reviews<sup>1,5,6</sup> included RCTs involving patients with COPD or chronic bronchitis, and the numbers of included RCTs that were relevant for the current report were 14 in one systematic review,<sup>1</sup> 11 in another,<sup>5</sup> and four in the third systematic review.<sup>6</sup> It should be noted that there was overlap in the RCTs included in these three systematic reviews (Appendix 5).

The single included primary study<sup>10</sup> was a single-centre, double-blind RCT involving hospitalized patients.

#### *Country of Origin*

One systematic review,<sup>1</sup> published in 2019, was from the UK and included RCTs from Europe, China and India. A second systematic review<sup>7</sup> published in 2019 was from Australia; countries of the included RCTs were not mentioned. One systematic review<sup>5</sup> published in 2015 was from Italy; countries of the included RCTs were not mentioned. Another systematic review<sup>4</sup> published in 2015 was from the US, and included RCTs from

Australia, Denmark, Iran, and the US. The last systematic review,<sup>6</sup> published in 2014, was from China; countries of the included RCTs were not mentioned.

The selected RCT,<sup>10</sup> published in 2016, was from Turkey.<sup>10</sup>

### *Population*

Three systematic reviews<sup>1,5,6</sup> included adult patients (majority of patients age > 50 years) with COPD or chronic bronchitis; the total number of patients in the systematic reviews ranged between 516 and 3,882; and the proportion of males in the included individual RCTs ranged between 43% and 93%.

Two systematic reviews<sup>4,7</sup> included hospitalized adult patients with acute lung disease and the total number of patients was 51 in one systematic review<sup>7</sup> and 200 in the second systematic review.<sup>4</sup> Of these, one systematic review<sup>7</sup> included adult patients, but the mean age or the proportion of males were not reported. In the second systematic review<sup>4,4</sup> the mean age ranged from 49 years to 74 years in the three included RCTs and was not reported in the last included RCT.

The selected RCT<sup>10</sup> included 38 hospitalized patients; the mean age was 69 years and the proportion of males was 92%.

### *Interventions and Comparators*

In four systematic reviews,<sup>1,4-6</sup> NAC was compared with placebo. In three systematic reviews,<sup>1,5,6</sup> oral NAC was used and in one systematic review<sup>7</sup> inhaled NAC was used. In one systematic review<sup>7</sup> NAC was compared with isotonic saline (IS) and also NAC plus IS was compared with IS alone; both agents were inhaled.

In the selected RCT<sup>10</sup> oral NAC was compared with placebo.

### *Outcomes*

Outcomes reported included mucus characteristics,<sup>7</sup> mucous expectoration,<sup>7</sup> oxygenation,<sup>7</sup> adverse events,<sup>1,4-7</sup> atelectasis,<sup>4</sup> hospitalization,<sup>1,4,10</sup> and mortality.<sup>1,7</sup>

## Summary of Critical Appraisal

Critical appraisal of the included studies is summarized below and details are presented in Appendix 3, Table 4 and Table 5.

Overall the systematic reviews were well conducted. In all five systematic reviews<sup>1,4-7</sup> the objective was clearly stated, a comprehensive literature search was conducted, article selection was described, a list of included studies was presented, study characteristics were described, and quality assessment of the studies were conducted and were found to be of variable quality. A list of excluded studies was presented in three systematic reviews<sup>1,4,7</sup> and not presented in two systematic reviews.<sup>5,6</sup> Article selection was done in duplicate in four systematic reviews,<sup>1,4,6,7</sup> and not in one systematic review.<sup>5</sup> Data extraction was done in duplicate in two systematic reviews,<sup>1,6</sup> and was unclear in three systematic reviews.<sup>4,5,7</sup> In three systematic reviews<sup>1,5,6</sup> meta-analyses were conducted, and in two systematic reviews<sup>4,7</sup> it was not feasible to conduct a meta-analysis. In three systematic reviews<sup>1,6,7</sup> it was reported that the authors had no conflicts of interest, in one systematic review<sup>5</sup> conflicts of interest were declared and a few of the authors were associated with industry, and in one systematic review<sup>4</sup> conflicts of interest were not reported.

In the selected RCT,<sup>10</sup> the objective and inclusion and exclusion criteria were presented; the patient characteristics, intervention, and outcomes were described; and a sample size calculation was conducted, however the appropriate number of patients could not be enrolled during the study period. It was a randomized study, but the randomization method was not described. The intervention and control were identical in appearance (both capsules). It was reported that all parties involved with the RCT were blinded to the study medication. Five percent of patients in the NAC group and 14% in the placebo group discontinued within the first three days of the trial, due to worsening conditions, and were excluded from the analysis. The imbalance in the discontinuation rates could impact results, however the direction of impact is unclear. Discontinuation was < 15% in both groups, and the associated reasons were reported. Intention-to-treat analysis was not conducted. It was reported that the authors had no conflicts of interest.

## Summary of Findings

Relevant study findings are summarized below and a table of the main study findings and authors' conclusions are presented in Appendix 4, Table 6 and Table 7. Of note, for studies comparing NAC with placebo, only the safety outcomes (not the effectiveness outcomes) were relevant of the current report and are presented here, as indicated in Table 1.

### *Clinical Effectiveness of Acetylcysteine (NAC)*

One relevant systematic review,<sup>7</sup> was identified regarding the clinical effectiveness of NAC compared with IS, in hospitalized patients with acute lung conditions (ventilated or post-operative). Relevant study findings are summarized and a table of the main study findings and authors' conclusions are presented in Appendix 4, Table 6 and Table 7.

#### **Mucous expectoration**

One RCT included in the selected systematic review<sup>7</sup> showed that ease of mucous expectoration tended to be better with NAC compared to IS (numerically better on the visual analog scale 10) in post-operative patients, however the statistical significance of the between group difference was not stated.

#### **Mucous characteristics**

One RCT included in the selected systematic review<sup>7</sup> reported that mucous viscosity improved with NAC but not with IS in post-operative patients, however the statistical significance of the between-group difference was not stated. The second RCT included in the selected systematic review<sup>7</sup> reported that neither NAC nor IS lowered mucous density in ventilated patients.

#### **Oxygenation**

One RCT included in the selected systematic review<sup>7</sup> reported that oxygenation (peripheral capillary oxygen saturation [SpO<sub>2</sub>] level) improved with NAC but not with IS, in post-operative patients, however the statistical significance of the between-group difference was not stated. The second RCT included in the selected systematic review<sup>7</sup> reported that oxygenation improved with NAC and there was no change with IS, in ventilated patients.

### *Safety of Acetylcysteine (NAC)*

Safety-related outcomes were available in all six included publications,<sup>1,4-7,10</sup> however, the types of outcomes reported varied. Adverse events, were reported in five publications,<sup>1,4-7</sup>

atelectasis was reported in one publication,<sup>4</sup> hospitalization was reported in three publications,<sup>1,4,10</sup> and mortality was reported in two publications.<sup>1,7</sup>

### **Atelectasis**

In the selected systematic review<sup>4</sup> that included hospitalized patients, one included RCT found that fewer patients developed atelectasis with NAC compared with IS (however, the between-group difference was non-significant), and a second included RCT found that there was no significant between-group difference in atelectasis with NAC compared with placebo.

### **Adverse events**

#### **COPD and chronic bronchitis**

Three systematic reviews<sup>1,5,6</sup> that included patients with COPD and chronic bronchitis compared NAC with placebo and reported on adverse events; findings were variable and inconsistent. In one systematic review<sup>1</sup> the odds ratios for adverse events in the individual included RCTs ranged from 0.36 to 2.05 and in majority of the RCTs the between-group differences were not statistically significant. In the second systematic review<sup>5</sup> the relative risk (RR) of adverse events with NAC compared to placebo was 0.94, and 95% confidence interval (CI) was 0.88 to 0.99. In the third systematic review,<sup>6</sup> the RR of adverse events was 1.30 (95% CI, 0.71 to 2.39); the between-group difference was statistically not significant.

#### **Hospitalized patients**

In one systematic review<sup>7</sup> there were no adverse events reported with either NAC or IS, in post-operative or ventilated patients. One systematic review<sup>4</sup> that included hospitalized patients, reported nausea in 10% of patients with NAC and 5% of the patients with placebo in one included RCT, and no adverse events during the study period in another included RCT. The single included primary study reported that 5% of patients in the NAC group and 14% in the placebo group discontinued within 3 days, due to worsening conditions and were excluded from the analysis; statistical significance of the difference in proportions was not presented.

### **Hospitalization**

In one systematic review<sup>4</sup> that included hospitalized patients, the median hospital stay was 6.0 days in the NAC group and 5.5 days in the placebo group (statistical significance of the findings was not reported). In the single included primary study,<sup>10</sup> that included hospitalized patients, the length of hospital stay was 10.5 days in the NAC group and 9.8 in the placebo group; the between-group difference was not statistically significant. Also, in this RCT, there were no significant between-group differences for the number of hospital admissions or time to admission during the six month follow-up.

#### **Mortality**

In one systematic review<sup>1</sup> that included patients with COPD or chronic bronchitis, the ORs for death for NAC compared with placebo in the individual included RCTs ranged from 0.13 to 3.24, and the between-group differences were not statistically significant.

In one systematic review<sup>7</sup> that included hospitalized patients with acute lung conditions, the in-hospital mortality rate was 50% in the NAC group, and 35% in the IS group (data from one included RCT); statistical significance of the findings was not reported.



### *Clinical Effectiveness of Nebulized versus Oral Acetylcysteine (NAC)*

No relevant evidence regarding the comparative clinical effectiveness of nebulized NAC versus oral NAC for patients requiring mucous secretion clearance were identified; therefore, no summary can be provided.

### Limitations

There was considerable overlap in the RCTs included in three systematic reviews,<sup>1,5,6</sup> hence findings are not exclusive, i.e. some of the same RCTs were used in assessing outcomes in these systematic reviews (Appendix 5).

There was a limited amount of evidence on the effectiveness of NAC compared with IS. No studies comparing NAC with pharmacologic agents (dornase alpha, guaifenesin, hypertonic saline or inhaled mannitol) or non-drug measures were identified.

Evidence on safety was available in terms of adverse events, atelectasis, hospitalization, and mortality, and not all of these outcomes were assessed in all of the included studies. One systematic review,<sup>4</sup> (Poole, 2019 #331) though well conducted, reported summary estimates for several mucolytic agents taken together, hence only estimates from the individual studies on NAC could be incorporated in this current report.

No studies comparing nebulized NAC with oral NAC were identified.

Findings need to be interpreted with caution given these limitations.

### Conclusions and Implications for Decision or Policy Making

A total of six relevant publications were identified regarding the clinical effectiveness or safety of NAC for patients requiring mucous secretion clearance. These comprised three systematic reviews<sup>1,5,6</sup> and one RCT<sup>10</sup> comparing NAC with placebo, one systematic review<sup>4</sup> comparing NAC with both placebo and IS, and one systematic review<sup>7</sup> comparing NAC with IS.

Relevant clinical effectiveness data were sparse. In one systematic review<sup>7</sup> that included hospitalized patients with acute lung disease, one included RCT reported that mucous expectoration, mucous viscosity, and oxygenation improved with NAC compared with IS, however the between-group differences were either not statistically significant or statistical significance was not reported.

In terms of safety, for patients with COPD or chronic bronchitis, or for hospitalized patients with acute lung disease, findings were variable with respect to adverse events for treatment with NAC compared with placebo, and definitive conclusions were not possible. Other safety-related outcomes for the comparison of NAC versus placebo, such as hospitalization, atelectasis, and mortality, were sparsely reported and results were variable; definitive conclusions were not possible. Similarly, evidence for the safety of NAC compared to IS was sparse and definite conclusions were not possible.

No relevant evidence regarding the comparative clinical effectiveness of nebulized NAC versus oral NAC for patients requiring mucous secretion clearance were identified.

Studies on idiopathic pulmonary fibrosis patients did not meet the inclusion criteria for the present report as idiopathic pulmonary fibrosis is generally associated with non-productive cough (i.e., dry; not bringing up mucus). However the findings from these studies may


provide some useful insights regarding treatment with NAC in comparison to placebo, and so are briefly discussed here. One systematic review<sup>12</sup> showed that in terms of risk of serious adverse events or mortality, there were no statistically significant between-group differences for NAC compared to placebo. One RCT<sup>13</sup> comparing NAC with placebo, reported numerically similar proportions of life-threatening adverse events (2% in each group), moderate adverse events (42% in NAC, 45% in placebo), and serious adverse events (5% in NAC, 3% in placebo); between-group differences were not tested statistically. One case-control study<sup>14</sup> compared pirferindone plus NAC with pirferindone alone, and reported that no adverse events were attributed to NAC.

High-quality studies are needed to definitively determine the clinical effectiveness and safety of NAC. Also studies comparing NAC with other active pharmacologic treatments or non-drug treatments are warranted.

## References

1. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary disease. *Cochrane Database Syst Rev*. 2019;5:Cd001287.
2. Rubin B. Secretion properties, clearance, and therapy in airway disease. *Transl Respir Med*. 2014;2:6.
3. Fahy JV. Airway Mucus Function and Dysfunction. *N Engl J Med*. 2010;363(23):2233 -2247.
4. Sathe NA, Krishnaswami S, Andrews J, Ficzero C, McPheeters ML. Pharmacologic Agents That Promote Airway Clearance in Hospitalized Subjects: A Systematic Review. *Respir Care*. 2015;60(7):1061-1070.
5. Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: A meta-analysis. *Eur Respir Rev*. 2015;24(137):451-461.
6. Shen. Effect of High/Low Dose N-Acetylcysteine on Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. *COPD*. 2014;11:351-358.
7. Tarrant BJ, Maitre CL, Romero L, et al. Mucoactive agents for adults with acute lung conditions: A systematic review. *Heart Lung*. 2019;48(2):141-147.
8. Shea BJ, Reeves BC, Wells G, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. *BMJ*. 2017;358:j4008. <http://www.bmj.com/content/bmj/358/bmj.j4008.full.pdf>. Accessed 2019 Jun 13.
9. Downs SH, Black N. The feasibility of creating a checklist for the assessment of the methodological quality both of randomised and non-randomised studies of health care interventions. *J Epidemiol Community Health*. 1998;52(6):377-384. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1756728/pdf/v052p00377.pdf>. Accessed 2019 Jun 13.
10. Ayfer Aytumur Z, Baysak A, Ozdemir O, Kose T, Sayiner A. N-acetylcysteine in patients with COPD exacerbations associated with increased sputum. *Wien Klin Wochenschr*. 2015;127(7-8):256-261.
11. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. *J Clin Epidemiol*. 2009;62(10):e1-e34.
12. Rogliani P, Calzetta L, Cavalli F, Matera MG, Cazzola M. Pirfenidone, nintedanib and N-acetylcysteine for the treatment of idiopathic pulmonary fibrosis: A systematic review and meta-analysis. *Pulm Pharmacol Ther*. 2016;40:95-103.
13. Behr J, Bendstrup E, Crestani B, et al. Safety and tolerability of acetylcysteine and pirfenidone combination therapy in idiopathic pulmonary fibrosis: A randomised, double-blind, placebo-controlled, phase 2 trial. *Lancet Respir Med*. 2016;4(6):445-453.
14. Sakamoto S, Muramatsu Y, Satoh K, et al. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: A case-control study. *Respirology*. 2015;20(3):445-452.

## Appendix 1: Selection of Included Studies



## Appendix 2: Characteristics of Included Publications

**Table 2: Characteristics of Included Systematic Reviews and Meta-Analyses**

First Author, Publication Year, Country	Study Designs and Numbers of Primary Studies Included	Population Characteristics	Intervention and Comparator(s)	Clinical Outcomes, <sup>a</sup> Length of Follow-Up
Poole, <sup>1</sup> 2019, UK	<p>SR included 14 relevant RCTs published between 1980 and 2014 (RCTs were: 3 Chinese, 2 European, 1 German, 1 Netherlands, 2 Indian, 2 Italian, 1 Swedish, 2 UK)</p> <p>Setting: Outpatient or general practice</p> <p>(This SR had a broad focus and included placebo-controlled RCTs; only RCTs relevant for this current report are included here)</p>	<p>Patients with COPD or chronic bronchitis</p> <p>N = 3,882 (primary study size ranged from 59 to 990)</p> <p>Age (mean) (years): 60 to 71 in 12 RCTs; age &gt;20 years in 1 RCT; and age &gt;50 years in 60% patients in 1 RCT.</p> <p>% Male: 59% to 93% in 13 RCTs, and not reported in 1 RCT</p>	<p>NAC versus placebo</p> <p>NAC dose: 200mg bid (2 RCTs), 200 mg tid (2 RCTs), 300mg bid (1 RCTs), 600 mg daily (5 RCTs), 600 mg bid (3 RCTs), 600 mg tid (1 RCT),</p>	<p>Adverse effects, hospitalization, mortality.</p> <p>Duration of primary studies: 3 months to 3 years.</p> <p>(Note: a number of studies could not be included in the analysis as the number of adverse events exceeded the numbers included in the treatment groups)</p>
Tarrant, <sup>7</sup> 2019, Australia	<p>SR included 2 relevant RCTs published between 1970 and 1992 (country: NR)</p> <p>Setting: hospital</p> <p>(This SR had a broad focus [mucoactive agents] and included several comparators; only RCTs relevant for this current report are included here)</p>	<p>Adults with acute lung condition (ventilated patients or post-operative patients)</p> <p>N = 51 (40 and 11 in the two primary studies)</p> <p>Age (years): NR</p> <p>% Male: NR</p>	<p>NAC versus IS (both nebulized)</p> <p>NAC (20%) 4 mL versus IS (0.9%) 4 mL in RCT in post-operative patients.</p> <p>(NAC [20%], 2 mL + IS, 8 mL) versus( IS [0.9%], 10 mL) in RCT in ventilated patients</p>	<p>Mucus characteristics, mucous expectoration, oxygenation</p> <p>Adverse events, mortality</p> <p>Durations of primary studies: unclear</p>
Cazzola, <sup>5</sup> 2015, Italy	<p>SR included 11 relevant RCTs published between 1976 and 2014 (country: NR)</p> <p>Setting: NR</p> <p>(This SR included placebo-controlled RCTs; only RCTs relevant for this current report are included here)</p>	<p>Patients with COPD or chronic bronchitis</p> <p>N = 2,828 (primary study size [patients who completed study] ranged from 45 to 964)</p> <p>Age (mean) (years):51 to 71 in 10 RCTs; and NR in 1 RCT</p> <p>% Male: 43% to 93%</p>	<p>NAC versus placebo</p> <p>NAC daily dose: 260 mg in 1 RCT, 400 mg in 2 RCTs 600 mg in 5 RCTs, 1,200 mg in 3 RCTs,</p>	<p>Adverse events</p> <p>Durations of primary studies: 4 months to 36 months</p>
Sathe, <sup>4</sup> 2015, US	<p>SR included 4 relevant studies (3 RCTs and 1 non-randomized study) published between 1966 and 2010 (Country: one</p>	<p>Hospitalized patients (with COPD exacerbations, asthma exacerbations, or post-operative)</p>	<p>NAC versus placebo (3 RCTs),</p> <p>Oral NAC 600 mg, bid; versus placebo (2</p>	<p>For NAC versus placebo studies: adverse events, hospital stay, atelectasis</p>

First Author, Publication Year, Country	Study Designs and Numbers of Primary Studies Included	Population Characteristics	Intervention and Comparator(s)	Clinical Outcomes, <sup>a</sup> Length of Follow-Up
	<p>RCT each in Australia Denmark, Iran and the US)</p> <p>Setting: hospital</p> <p>(This SR had a broad focus [assessed various pharmacologic agents that promote airway clearance]; only RCTs relevant for this current report are included here)</p>	<p>N = 269 (=50+50+129+40) enrolled, and 200 (=50+50+60+40) final number of patients</p> <p>Age (years) (mean): 49, 53 and 74 for 3 studies; and NR for 1 study</p> <p>% Male: NR</p>	<p>RCTs).</p> <p>Oral NAC 1,200 mg on day before surgery, and oral or intravenous NAC 200 mg, tid for 6 days or until discharge (1 RCT)</p> <p>-----</p> <p>NAC versus saline (1 study) NAC 10% solution, 2 ml every 2 h for 10 doses after anesthesia recovery and physiologic saline 2 mL every 2 h</p>	<p>NAC versus saline study: atelectasis, nausea</p>
Shen, <sup>6</sup> 2015, China	<p>SR included 4 relevant RCTs published between 1985 and 2013 (country: NR)</p> <p>Setting: NR</p> <p>(This SR included placebo controlled RCTs; only RCTs relevant for this current report are included here)</p>	<p>Patients with COPD or chronic bronchitis</p> <p>N = 516 (primary study size ranged from 91 to 169)</p> <p>Age (mean) (years):51 to 71 in 10 RCTs; and NR in 1 RCT</p> <p>% Male: 43% to 93%</p>	<p>NAC versus placebo</p> <p>NAC dose: 200 mg tid (1 RCT), 300 mg bid (1 RCT), 600 mg daily (1 RCT), 600 mg bid (1 RCT),</p>	<p>Adverse events (gastrointestinal)</p> <p>Durations of primary studies: 5 months to 1 year</p>

bid = two times daily; COPD = chronic obstructive pulmonary disease; IS = isotonic saline; NAC = N-acetylcysteine; neb = nebulizer; NR = not reported; RCT = randomized controlled trial; SR = systematic review; tid = three times daily.

<sup>a</sup>Only outcomes relevant for the current report are included here.

**Table 3: Characteristics of Included Primary Clinical Study**

First Author, Publication Year, Country	Study Design	Population Characteristics	Intervention and Comparator(s)	Clinical Outcomes, <sup>a</sup> Length of Follow-Up
Randomized controlled trials				
Ayfer Aytemur, <sup>10</sup> 2015, Turkey	<p>RCT, double blinded, single center</p> <p>Setting: single center</p>	<p>Patients with COPD who were hospitalized for their current exacerbation</p> <p>N = 42 (38 were analyzed; 19 in each group)</p> <p>Age (mean) (years):</p>	<p>NAC versus placebo</p> <p>NAC capsules 200 mg tid for 30 days</p>	<p>Hospitalization</p> <p>Follow-up = 6 m</p>

First Author, Publication Year, Country	Study Design	Population Characteristics	Intervention and Comparator(s)	Clinical Outcomes, <sup>a</sup> Length of Follow-Up
		68.6 in NAC group and 69.4 in placebo group  % Male: 89 in NAC group and 95% in placebo group  Duration of COPD (years): 19 ±14.9 in NAC group and 11.4 ± 7.5 in placebo group		

COPD = chronic obstructive pulmonary disease; m = month; NAC = N acetylcysteine; RCT = randomized controlled trial; tid = three times daily.

<sup>a</sup>Only outcomes relevant for the current report are included here.

## Appendix 3: Critical Appraisal of Included Publications

**Table 4: Strengths and Limitations of Systematic Reviews and Meta-Analyses using AMSTAR 2<sup>8</sup>**

Strengths	Limitations
Poole, <sup>1</sup> 2019, UK	
<ul style="list-style-type: none"> <li>• The objective was clearly stated</li> <li>• Multiple databases (MEDLINE, EMBASE, Airways Group Trials Register, PsychINFO, CINAHL) were searched up to April 2019 (a previous version of the review included searches up to July 2014 and this current version included also additional search between July 2014 to April 2019). In addition proceedings of major respiratory conferences, and reference list of included studies and reviews, were searched.</li> <li>• Study selection was described and a flow chart was presented</li> <li>• A list of included studies was provided</li> <li>• A list of excluded studies was provided</li> <li>• Article selection was done independently by two reviewers</li> <li>• Data were extracted by two reviewers. This Cochrane review was an update from a previous Cochrane review and the extracted data were double checked against the original publication.</li> <li>• Quality assessment was conducted using the Cochrane risk of bias tool; the studies were of variable quality</li> <li>• Characteristics of the included studies were presented</li> <li>• Meta-analysis was conducted. However as all mucolytic agents were included in the meta-analysis, pooled estimates for NAC alone could not be presented; instead, individual estimates were considered.</li> <li>• Publication bias was explored using Funnel plots when feasible (i.e., &gt; 10 studies were available). The quality of the studies was variable.</li> <li>• It was mentioned the authors had no known conflicts of interest</li> </ul>	<ul style="list-style-type: none"> <li>• No apparent major limitations</li> </ul>
Tarrant, <sup>7</sup> 2019, Australia	
<ul style="list-style-type: none"> <li>• The objective was clearly stated</li> <li>• Multiple databases (Medline, Embase, CINAHL and CENTRAL) up to January 2018. In addition grey literature was searched.</li> <li>• Study selection was described and a flow chart was presented</li> <li>• A list of included studies was provided</li> <li>• A list of excluded studies was provided</li> <li>• Article selection was done by two reviewers</li> <li>• Quality assessment was conducted using the Cochrane risk of bias tool (7 items). For the 7 items, risk of bias was low for 4 items, unclear for 2 items, and high for 2 items for both of the two relevant RCTs. Risk of bias was low for some items</li> </ul>	<ul style="list-style-type: none"> <li>• Unclear if data extraction was done in duplicate</li> <li>• Unclear if publication bias was explored</li> </ul>



Strengths	Limitations
<p>and unclear or high for some items.</p> <ul style="list-style-type: none"> <li>Characteristics of the included studies were presented, however lacked some details (e.g., age of the population, duration of the study)</li> <li>Narrative synthesis was done (the authors mentioned that if meta-analysis was not possible, a narrative synthesis would be done)</li> <li>It was mentioned the authors had no known conflicts of interest</li> </ul>	
Cazzola, <sup>5</sup> 2015, Italy	
<ul style="list-style-type: none"> <li>The objective was clearly stated</li> <li>The search was performed on PubMed and Google scholar up to July 2014. Also relevant reviews and meta-analysis were examined to identify studies.</li> <li>Study selection was described and a flow chart was presented</li> <li>A list of included studies was provided</li> <li>Quality assessment was conducted using the Jadad score (scale: 1 to 5, with higher scores indicating better quality). Scores ranged from 1 to 4, with 55% of the studies having a score of 4</li> <li>Characteristics of the included studies were presented</li> <li>Meta-analysis was conducted</li> </ul>	<ul style="list-style-type: none"> <li>A list of excluded studies was not provided</li> <li>Unclear if article selection was conducted in duplicate</li> <li>Unclear if data extraction was done in duplicate</li> <li>Publication bias does not appear to have been examined</li> <li>Declarations were provided by two of the seven authors, and both received fees (not related to the current review) from industry</li> </ul>
Sathe, <sup>4</sup> 2015, US	
<ul style="list-style-type: none"> <li>The objective was clearly stated</li> <li>Multiple databases (MEDLINE, EMBASE) were searched from 1970 until July 2014. Also, reference lists of include studies and relevant narrative and systematic reviews and meta-analysis were searched.</li> <li>Study selection was described and a flow chart was presented</li> <li>A list of included studies was provided</li> <li>A list of excluded studies was provided</li> <li>Article selection was done independently by two reviewers</li> <li>Quality of the studies was assessed by independently by two reviewers, using the Cochrane Risk of Bias tool for RCTs and the Newcastle-Ottawa scale for non-randomized studies. The majority of the studies were judged to be of low quality.</li> <li>Characteristics of the included studies were presented</li> </ul>	<ul style="list-style-type: none"> <li>Unclear if data extraction was done in duplicate</li> <li>Meta-analysis was not conducted</li> <li>Publication bias does not appear to have been examined</li> <li>Conflicts of interest of the authors were not presented</li> </ul>
Shen, <sup>6</sup> 2014, China	
<ul style="list-style-type: none"> <li>The objective was clearly stated</li> <li>Multiple databases (MEDLINE, EMBASE, Cochrane library) were searched until August 2013. Also, reference lists of include studies and relevant reviews were searched.</li> <li>Study selection was described and a flow chart was presented</li> <li>A list of included studies was provided</li> </ul>	<ul style="list-style-type: none"> <li>A list of excluded studies was not provided</li> <li>Publication bias does not appear to have been examined</li> </ul>

Strengths	Limitations
<ul style="list-style-type: none"> <li>• Article selection was done independently by two reviewers</li> <li>• Data was extracted and rechecked independently by two reviewers</li> <li>• Quality of the studies was assessed by independently by two reviewers using the Cochrane Allocation Concealment Scale and Jadad score (scale 1 to 5, with higher scores indicating better quality). Jadad score ranged from 2 to 4 with 75% of the studies having score of 4.</li> <li>• Characteristics of the included studies were presented</li> <li>• Meta-analysis was conducted</li> <li>• The authors mentioned that there were no conflicts of interest</li> </ul>	

NAC = acetylcysteine; RCTs = randomized controlled trials.

**Table 5: Strengths and Limitations of Clinical Study using Downs and Black checklist<sup>9</sup>**

Strengths	Limitations
Ayfer Aytemur, <sup>10</sup> 2015, Turkey	
<ul style="list-style-type: none"> <li>• The objective was clearly stated</li> <li>• The inclusion and exclusion criteria were stated</li> <li>• Patient characteristics, intervention and outcomes were described</li> <li>• Randomized study but randomization procedure was not described</li> <li>• Double-blinded – all parties were blinded to the study medication the patients received</li> <li>• Sample size calculation was conducted, however, the appropriate number of patients could not be reached during the study period.</li> <li>• Discontinuation and the associated reasons were reported; 5% in the NAC group and 14% in the placebo group were excluded as they had worsened and had to be admitted to the ICU and intubated.</li> <li>• The authors mentioned that there were no conflicts of interest</li> <li>• <i>P</i> values were reported</li> </ul>	<ul style="list-style-type: none"> <li>• Intention-to-treat analysis was not conducted</li> </ul>

ICU = intensive care unit; NAC = acetylcysteine.

## Appendix 4: Main Study Findings and Authors' Conclusions

**Table 6: Summary of Findings Included Systematic Reviews and Meta-Analyses**

Main Study Findings <sup>a</sup>	Authors' Conclusion
Poole, <sup>1</sup> 2019, UK	
<p><b>Comparison of treatment with NAC (a mucolytic agent) versus placebo, with respect to safety for patients with COPD or chronic bronchitis (from SR).</b></p> <p><b>Adverse effects</b> were reported in 12 RCTs. In 2 RCTs the ORs were 0.36 and 0.54 and the between-group differences were statistically significant, favoring NAC. However, in 9 RCTs, the ORs ranged from 0.48 to 2.05, and the between-group differences were statistically non-significant. In 1 RCT there were zero adverse events reported in both groups.</p> <p><b>Hospitalization</b> during study period was reported in 4 RCTs. In 1 RCT the OR was 0.32 and the between-group difference was statistically significant favoring NAC; however in 3 RCTs, ORs ranged from 0.61 to 0.91 and the between-group differences were statistically non-significant.</p> <p><b>Death</b> during study period was reported in 8 RCTs. In 6 RCTs, ORs ranged from 0.13 to 3.24 and the between-group differences were statistically non-significant. In 2 RCTs, there were zero adverse events reported in both groups.</p>	<p>"There was no clear difference between mucolytics and placebo for mortality, but the confidence interval is too wide to confirm that treatment has no effect on mortality" (p. 2)</p> <p>"People taking mucolytics did not experience more unwanted side effects than those taking placebo." (p. 3)</p>
Tarrant, <sup>7</sup> 2019, Australia	
<p><b>Comparison of treatment with nebulized NAC versus nebulized isotonic saline (IS) with respect to efficacy and safety for patients with acute lung conditions (from SR with 2 relevant RCTs)</b></p> <p><b>Mucus characteristics</b> One RCT compared NAC with IS, and showed that after two days of use of either NAC or IS following thoracic or abdominal surgery, with NAC the mean mucus weight (g) increased (mean ± standard deviation [SD] from 2.65 ± 3.47 to 7.50 ± 6.29; <i>P</i> = 0001) and with IS there was little change (mean ± SD: from 3.45 ± 2.16 to 3.55 ± 2.99; not statistically significant); and mucus viscosity improved with NAC but not with IS, however the significance of the between-group difference was not stated in either instance. One RCT compared NAC with IS, and showed that during invasive ventilation neither NAC nor IS lowered mucus density after three doses over 24 hours.</p> <p><b>Mucous expectoration</b> One RCT compared NAC with IS, and showed that after two days of use of either NAC or IS following thoracotomy or laparotomy, with NAC the ease of mucous expectoration improved (3.75 cm) and there was little improvement with IS (0.27 cm), using visual analog scale of 10, however the significance of the between-group difference was not stated</p> <p><b>Oxygenation</b> One RCT showed that, post thoracic or abdominal surgery, oxygenation (SpO<sub>2</sub> [%]) improved with NAC (from 91.6 ± 3.75 to 93.96 ± 2.67) and there was no change with IS (93.08 ± 3.23 to 93.35 ± 3.64), but the significance of the between group difference was not reported.</p>	<p>The authors reported that for post-surgery patients with acute lung conditions, mucous weight, viscosity, and expectoration; and oxygenation improved with NAC and there was little change with IS, however the significance of between-group differences were not reported.</p> <p>Also, for ventilated patients with acute lung conditions there was no improvement in mucous density with either NAC or IS; there was some improvement in oxygenation with NAC and little change with IS, however the between-group difference was not statistically significant.</p> <p>There were no AEs reported with either NAC or IS in post-operative or ventilated patients.</p>

Main Study Findings <sup>a</sup>	Authors' Conclusion																
<p>One RCT showed that, during invasive ventilation, oxygenation (SpO<sub>2</sub>) improved with NAC (from 93.8 ± 2.7 to 95.1 ± 2.6) and there was no change with IS (94.0 ± 2.2 to 93.9 ± 2.5), however the between-group difference was not statistically significant (<i>P</i> = 0.30)</p> <p><b>Adverse events</b> There were no AEs reported with either NAC or IS, in post-operative or ventilated patients.</p> <p><b>Mortality</b> In one RCT, for the ventilated patients who had a diagnosis of pneumonia or sepsis, the in-hospital mortality rate was 50% in the NAC group and 35% in the IS group; statistical significance of the findings was not reported.</p>																	
Cazzola, <sup>5</sup> 2015, Italy																	
<p><b>Comparison of treatment with NAC (a mucolytic agent) versus placebo, with respect to safety for patients with COPD or chronic bronchitis</b> (from SR).</p> <table border="1" data-bbox="110 919 940 1121"> <thead> <tr> <th>NAC dose</th> <th>No. of RCTs</th> <th>RR (95% CI)</th> <th>Heterogeneity, I<sup>2</sup> (%)</th> </tr> </thead> <tbody> <tr> <td>All (260 mg to 1,200 mg daily)</td> <td>11</td> <td>0.94 (0.88 to 0.99)</td> <td>5</td> </tr> <tr> <td>Low (260 mg to 600 mg daily)</td> <td>8</td> <td>0.93 (0.89 to 0.97)</td> <td>0</td> </tr> <tr> <td>High (1,200 mg daily)</td> <td>3</td> <td>1.11 (0.89 to 1.39)</td> <td>0</td> </tr> </tbody> </table> <p>Adverse events reported included gastrointestinal disorders, respiratory disorders, and other disorders (such as pyrosis, joint and muscle pain, and dizziness)</p>	NAC dose	No. of RCTs	RR (95% CI)	Heterogeneity, I <sup>2</sup> (%)	All (260 mg to 1,200 mg daily)	11	0.94 (0.88 to 0.99)	5	Low (260 mg to 600 mg daily)	8	0.93 (0.89 to 0.97)	0	High (1,200 mg daily)	3	1.11 (0.89 to 1.39)	0	<p>"NAC was well tolerated and the risk of adverse reactions was not dose dependent". (p. 451)</p>
NAC dose	No. of RCTs	RR (95% CI)	Heterogeneity, I <sup>2</sup> (%)														
All (260 mg to 1,200 mg daily)	11	0.94 (0.88 to 0.99)	5														
Low (260 mg to 600 mg daily)	8	0.93 (0.89 to 0.97)	0														
High (1,200 mg daily)	3	1.11 (0.89 to 1.39)	0														
Sathe, <sup>4</sup> 2015, US																	
<p><b>Comparison of treatment with NAC (a mucoactive agent) versus placebo, or saline with respect to adverse events for hospitalized patients requiring airway clearance</b> (from SR).</p> <p><b>Atelectasis</b> In one RCT, 4 of 20 patients in the NAC group and 9 of 20 patients in the saline group developed atelectasis, however the between-group difference was reported as not significant. In one RCT there was no significant difference in atelectasis between the NAC group and the placebo group.</p> <p><b>Adverse events</b> 2 patients in the NAC group and 1 patient in the placebo group had nausea; both groups comprised 20 patients each (1 RCT) AE not mentioned in 1 RCT (NAC vs. placebo) No adverse effects were reported during the study period (1 RCT: NAC vs. placebo) AE not mentioned in 1 RCT (NAC versus saline)</p>	<p>For hospitalized patients requiring airway clearance Sathe et al. mentioned that "Further research with clearly characterized populations and interventions is needed to understand the potential benefits and adverse effects of mucoactive agents." (p. 1061)</p>																

Main Study Findings <sup>a</sup>			Authors' Conclusion
<b>Hospital stay</b> Hospital stay (median) was 6.0 days in the NAC group and 5.5 days in the placebo group ( <i>P</i> value not reported) (from 1 RCT)			
Shen, <sup>6</sup> 2014, China			
<b>Comparison of treatment with NAC (a mucolytic agent) versus placebo, with respect to adverse events (GI disorders) for patients with COPD or chronic bronchitis (from SR).</b>			"GI disorders including diarrhea, reflux esophagitis, and gastric complications were reported in some studies, but NAC did not significantly increase the risk of such adverse reactions" (p. 355)
No. of RCTs	RR (95% CI)	Heterogeneity, I <sup>2</sup> (%)	
4	1.30 (0.71 to 2.39)	0	

CI = confidence interval; COPD = chronic obstructive pulmonary disease; GI = disorder; IS = isotonic saline; NAC = N-acetylcysteine; OR = odds ratio; RCT = randomized controlled trial; RD = risk difference; RR = relative risk; SpO<sub>2</sub> = peripheral capillary oxygen saturation; SR = systematic review.

<sup>a</sup>Only outcomes of interest for the current report are included here (i.e., clinical effectiveness outcomes with NAC compared to placebo or no treatment are not reported here).

**Table 7: Summary of Findings of Included Primary Clinical Study**

Main Study Findings <sup>a</sup>			Authors' Conclusion	
<b>Randomized controlled trial</b>				
Ayfer Aytemur, <sup>10</sup> 2015, Turkey				
<b>Comparison of treatment with NAC versus placebo, with respect to hospitalization for COPD patients who were hospitalized for their current exacerbation (RCT)</b>			"In conclusion, we found that NAC given at a daily dose of 600 mg to patients with COPD exacerbations and with a high volume of sputum production did not affect symptoms, pulmonary function, length of hospital stay, and exacerbation rate during the follow-up period." (p.260)	
Outcome	Effect			<i>P</i> value
	NAC	Placebo		
Length of hospital stay (d)	10.5 ± 3.8	9.8 ± 3.0		0.52
Number of hospital admissions during 6 m FU	0.9 ± 1.1	0.6 ± 0.9		0.42
Time (d) to hospital admission during 6 m FU	45.6 ± 67.2	24.6 ± 41.5	0.37	
Unclear if effect was expressed as mean and standard deviation				

d = day; m = month; NAC = N-acetylcysteine.

<sup>a</sup>Only outcomes of interest for the current report are included here (i.e., clinical effectiveness outcomes with NAC compared to placebo or no treatment are not reported here).

## Appendix 5: Overlap between Included Systematic Reviews

**Table 8: Primary Study Overlap between Included Systematic Reviews**

Primary Study <sup>a</sup> Citation	Systematic Review Citation		
	Poole, <sup>1</sup> 2019	Cazzola, <sup>5</sup> 2015	Shen, <sup>6</sup> 2015
Babolini, 1980	X	X	
Bachh, 2007	X	X	
Boman, 1983	X	X	
Decramer, 2005	X	X	X
Grassi, 1976	X	X	X
Hansen, 1994	X	X	X
Jackson, 1984	X		
Johnson, 2016	X		
McGavin, 1985	X	X	X
Meister, 1986	X		
Nowak, 1999	X		
Pela, 1999	X	X	X
Rasmussen, 1988	X	X	X
Schermer, 2009	X	X	X
Tse, 2013	X	X	X
Xu, 2014	X		
Zheng, 2014	X	X	

X indicates studies that were included in the systematic review.

<sup>a</sup>Primary studies which reported on outcomes of relevance to the current report.